Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Gereon Nelles · Lukas Schmitt · Thomas Humbert · Veit Becker · Petra Sandow · Karin Bornhoevd · Dirk Fritzsche · Barbara Schäuble · on behalf of the TOPMATMIG-0001 investigators

Received: 16 August 2009 / Accepted: 28 September 2009 / Published online: 6 November 2009 © Springer-Verlag 2009

Abstract The majority of patients with migraine headaches are treated in non-specialized institutions though data on treatment outcomes are largely derived from tertiary care centers. The current non-interventional study explores efficacy and tolerability outcomes of patients with episodic migraines receiving topiramate as preventive agent in a general practice setting. A total of 366 patients (87% female, mean age 41.8 ± 11.6 years) were eligible for migraine prevention and treated with flexible dose topiramate for 6 months (core phase), and optionally for a total of 12 months (follow-up phase). Overall, 261 patients (77.7% of safety analysis set, SAF) completed the core phase. Reasons for discontinuation included adverse events (2.1%), lost to follow-up (1.8%), other reasons (1.5%), and end of therapy (0.3%) though in the majority of patients who discontinued no reasons were listed. The median daily dose at endpoint was 50 mg/day (range, 25–187.5 mg/day). The median days with migraine headaches decreased from 6.0 to 1.2 days (p < 0.001), median pain intensity score decreased from 17.0 to 3.2 points (p < 0.001). In women with reported menstruation-associated migraine, the median number of migraine attacks decreased from 4.0 to 0.9 (p < 0.001). Absenteeism as well as triptan use decreased significantly, and significant improvements in activities of daily living and quality of life were reported. The most frequently reported AEs were paraesthesia (4.2%) and nausea (3%). Results suggest that migraine prevention with topiramate in a general practice is generally well tolerated and associated with a significant improvement in migraine headaches and related functional impairment.

Keywords Migraine prevention · Topiramate · Open label study · Menstruation

Abbreviations
AE Adverse event
CRF Case report form
CP Core phase
EAS Efficacy analysis set
FUAS Follow up analysis set
EFF Efficacy population
HIT Headache impact test
IHS International headache society
IQR Interquartile range
LOCF Last observation carried forward
SAF Safety population
SD Standard deviation
Introduction

Migraine is a common neurological disorder affecting approximately 12 to 14% of all women and 6 to 8% of all men in western societies [1, 2]. It is reported that 43% of women and 18% of men suffer from migraine at some point in their lives [3, 4]. Due to the negative impact on quality of life, daily activity and work-related productivity, timely diagnosis, and effective management of the patient is important [5–7]. Next to non-pharmacological interventions, effective acute and preventive treatments play an important role [8]. Migraine prevention not only reduces the frequency, severity, and duration of attacks, but was shown to reduce migraine-related socio-economic burden [9]. Pharmacological prevention of migraine is recommended by several professional societies if patients fulfill criteria for preventive treatment [10]. Multiple effective drugs are available, however, they differ in the level of scientific evidence to support their use in migraine prevention as well as in clinical profile. Preventive medication frequently used and recommended by professional bodies include beta-blockers, calcium channel blockers, tricyclic antidepressants, or antiepileptic drugs, such as valproate and topiramate [11–16]. Topiramate is a fructopyranose sulfamate with proven efficacy in migraine prevention. This was demonstrated in several randomized, controlled clinical trials [12, 13, 18]. Most commonly, treatments are used in monotherapy, however, there is some emerging data that in certain individuals add-on therapy might be appropriate [17].

Despite considerable burden of disease and available class I evidence, only 1 in 5 patients who fulfill the criteria for preventive migraine therapy are treated and considerable underrecognition of the disease itself is reported [19].

Though general practitioners play an important role in disease recognition and initial treatment [20], there are only few data on patient outcomes with topiramate derived from non-specialized centers [21]. Therefore, the present study is designed to explore tolerability and efficacy outcomes in outpatients treated with topiramate for migraine prevention in a naturalistic setting.

Methods

Study design

This was a prospective, multicenter non-interventional study carried out between February 2006 and December 2007 in Germany. Patients were followed-up during a 6 months core phase with an optional follow-up for up to 12 months in total. The decision to extend the treatment period from 6 to 12 months was based on physicians’ and patients’ assessments of therapy at month 6. No formal criteria were established. Patients were evaluated at baseline, after approximately 2, 4, 8, 12 weeks, and after 6 months with optional follow-up after 9 and 12 months. Patients’ demographics, disease characteristics including frequency of migraine attacks, migraine auras and associated symptoms, pain intensity, quality of life, absenteeism, previous and currently used preventive agents, type and frequency of intake of acute medication, other concomitant medication, and adverse events (AEs) were recorded in the electronic case report form (CRF). Data on frequency, severity, and symptoms of all headaches or auras, and the use of acute medications were based on patient’s diaries, which were transcribed by the investigator into the patient’s CRF. All visits were office-based except for Visit 2 (2 weeks) and Visit 4 (8 weeks), which were optional and by phone.

Patient selection

Patients were selected from 183 non-academic neurology, anesthesiology, or general practices in Germany. Patients, aged 18 years and older were documented if they carried a diagnosis of episodic migraine headaches and their diagnosis was based on the International Headache Society (IHS) criteria [22]. The patients were prospectively followed-up for 6 months and optionally for 12 months if migraine preventive therapy was indicated based on guidelines published by the German Neurological Society (DGN) [23] and the German Society for Headache (DGKM) [10]. Migraine headache, migraine attacks, and auras were defined based on the IHS definitions. Patients with known hypersensitivity or other contraindications prohibiting topiramate therapy were excluded from participation.

Treatment

Topiramate (Topamax® Migräne; Janssen-Cilag GmbH, Germany) was recommended to be taken based on the summary of product characteristics. Titration rate and final dose were guided by the patient’s clinical response to topiramate therapy.

Concomitant therapies

Patients were allowed to take acute rescue medications, such as analgesics, non-steroidal anti-inflammatory drugs, triptans, ergotamine derivatives, opioids, and other rescue medication during any phase in the study. The use of acute rescue medication had to be recorded in the patient diary together with disease-related information (e.g. migraine attack information).
Ethics

The study was conducted in accordance with the “Empfehlungen zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen (Recommendation for the planning, implementation and evaluation of non-interventional studies with medicinal products)” of the BfArM (Federal Institute for Drugs and Medical Devices) dated 12 November 1998 and the “Notice to Marketing Authorisation Holders—Pharmacovigilance Guidelines” issued by the EMEA (European Agency for the Evaluation of Medicinal Products). Janssen-Cilag has notified the BfArM about the conduct of the study. An independent ethics committee (Freiburg, Germany) evaluated the study protocol and granted approval for study conduct.

Outcome measures

The primary objective of the study was to explore efficacy and tolerability outcomes of flexibly dosed topiramate in routine clinical practice. Exploratory efficacy outcome measures included the change in the median number of monthly migraine attacks from baseline to the last visit of the core phase (6 months) and to the last visit of the optional follow-up phase (for a maximum of 12). In addition, changes in monthly migraine days, changes in frequency of migraine attacks, changes in pain intensity score were captured; the percentage of patients with ≥50%, ≥75%, and ≥90% reduction in the mean number of monthly migraine attacks (categorical responder rates). Types and frequencies of AEs, the dosage of topiramate in daily practice, and the impact of migraine on activities of daily living and on the quality of life (HIT-6™) were analyzed. Impairment of daily life was measured with the impairment score. The impairment score was calculated as (days with severe impairment × 3) + (days with moderate impairment × 2) + (days with slight impairment × 1), normalized to 28 days. The HIT-6™ is a tool to measure the impact of headaches on daily life. The questionnaire consists of 6 questions with a 5-point scale (“never”, “rarely”, “sometimes”, “very often”, and “always”). The sum of the total score ranges between 36 (no impact) and 78 (severe impact).

Statistical analyses and data management

Statistics

All statistical tests were exploratory. No adjustment for multiple testing was performed. Last observation carried forward (LOCF) analyses were performed for treatment effect parameters using the last available post-dose value of the respective parameter as the endpoint of analysis. No other imputation of data was performed. Continuous variables were described by the total number of observations (N), minimum, maximum, mean, standard deviation (SD), median, and interquartile range (IQR). Categorical variables were described by the total number of patients, and by the number and the proportion of patients for each category. Changes from baseline were analyzed by exploratory Wilcoxon signed rank tests (significance level: 0.05). Data regarding AEs, previous and concomitant diseases, and surgical procedures were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 10.1. The incidence of AEs was computed together with its binomial 95% confidence interval.

Data sets analyzed

Available data of all patients were listed in patient data listings. For analysis, the following populations were defined: a Safety population (SAF), which included all patients for whom documentation was started and for whom the intake of at least one dose of topiramate was documented, and a Treatment effect population (EFF), which included all SAF patients for whom at least one treatment effect variable was documented after the start of topiramate treatment. In addition, a subanalyses was stipulated to compare women with menstruation-associated migraine at baseline versus women with migraines not associated with menstruation at baseline. An overview on the study populations is given in Fig. 1.

Fig. 1 Flowchart showing an overview on the study population
Results

A total of 336 out of 373 patients evaluated received topiramate (SAF). In 34 patients, no post-baseline efficacy outcomes data were documented. Based on this, the EFF-analysis comprised 302 patients (Fig. 1). A total of 261 patients (77.7% of SAF) completed the 6 months observational period (core phase), whereas 75 patients (22.3% of SAF) discontinued prematurely. Reasons for premature discontinuation were: AEs (N = 7, 2.1% of SAF), lost to follow-up (N = 6, 1.8%), other reasons (N = 5, 1.5%), and end of therapy (N = 1, 0.3%). In the majority of patients though, a reason for discontinuation was not obtainable. A total of 203 patients (60.4% of SAF) had data available at Visit 7 (Month 9) and 183 patients (54.5% of SAF) completed the 12 months.

Baseline demographics, disease characteristics, and previous treatment

Pertinent baseline data and disease characteristics of the 302 patients treated in the core phase (ITT-analysis) are summarized in Tables 1 and 2. As much as 29.5% of patients reported migraine headaches with auras and in 36.8% of women menstruation-associated migraines were reported.

In the EFF, 139 patients (46.0% of EFF) had received migraine preventive treatment in the past (Table 3). As much as 82.7% (N = 115) had been exposed to 1 or 2 therapeutic attempts with beta blockers and 5.0% even to 3 to 4 attempts. Antidepressants were used at least once by 43 patients (30.9% of pretreated EFF patients). As much as 37 patients (26.6%) used Ca²⁺-channel blockers and 23 patients (16.5%) used anticonvulsant drugs other than topiramate at least once (Table 3). At baseline, a total of 20 patients (6.6% of 302 EFF patients) received preventive migraine treatment other than topiramate. The treatment with these drugs continued during the study phase. Due to the low number of patients, no subanalyses was added.

Table 1 Demographic data

|                | SAF N = 336 | EFF N = 302 |
|----------------|-------------|-------------|
| Gender (N, %)  |             |             |
| Female         | 292 (76.9)  | 266 (88.1)  |
| Male           | 44 (13.1)   | 36 (11.9)   |
| Age (years)    |             |             |
| Mean ± SD      | 41.8 ± 11.6 | 41.5 ± 11.4 |
| Median (range) | 42 (18, 71) | 42 (18, 71) |
| Height (cm)    |             |             |
| Mean ± SD      | 168.6 ± 7.1 | 168.5 ± 7.0 |
| Median (range) | 168 (150, 193) | 168 (150, 193) |
| Weight (kg)    |             |             |
| Mean ± SD      | 69.1 ± 11.6 | 68.6 ± 11.3 |
| Median (range) | 68 (46, 110) | 67 (46, 107) |
| BMI (kg/m²)    |             |             |
| Mean ± SD      | 24.3 ± 3.7  | 24.2 ± 3.6  |
| Median (range) | 23.5 (17.7, 41.3) | 23.4 (17.7, 38.2) |

Percentages relate to the number of patients in the respective population

Table 2 Disease characteristics

|                        | SAF N = 336 | EFF N = 302 |
|------------------------|-------------|-------------|
| Age at first diagnosis of migraine (years) |             |             |
| N                      | 328         | 295         |
| Mean ± SD              | 24.1 ± 9.0  | 24.0 ± 8.6  |
| Median (range)         | 22 (8, 53)  | 22 (8, 53)  |
| Time since diagnosis (years) |             |             |
| N                      | 328         | 295         |
| Mean ± SD              | 17.5 ± 11.0 | 17.4 ± 10.7 |
| Median (range)         | 17 (0, 52)  | 17 (0, 52)  |
| Migraine associated with menstruation (women only) (N, %) |             |             |
| No                     | 183 (62.7)  | 167 (62.8)  |
| Yes                    | 107 (36.6)  | 98 (36.8)   |
| Aura (N, %)            |             |             |
| No                     | 234 (69.6)  | 213 (70.5)  |
| Yes                    | 102 (30.4)  | 89 (29.5)   |

a Percentages relate to the number of female patients in the respective population

b Percentages relate to the number of patients in the respective population

Topiramate dose

At baseline, the majority of patients (N = 259, 85.8% of 302 EFF patients) started on the recommended daily dose of 25 mg: 33 patients (10.9% of EFF) started with 50 mg, 6 patients (2.0%) started on 100 mg, and 3 (1.0%) patients started on 200 mg. One patient had an initial dose of 12.5 mg/day. After 6 months of treatment (N = 261), 44.4% of patients took a total daily dose of 50 mg, 24.9% took 100 mg/day, and 13.0% took 75 mg/d. The mean daily dose was 58.7 ± 27.4 mg/day at endpoint.

Efficacy outcomes

Number of migraine attacks

The median (IQR) number of migraine attacks per month declined gradually from 4.0 (3.0–6.0) at baseline to 0.9 (0.4–1.8) after 6 months of treatment (Fig. 2a). At the 12-month visit, a further slight improvement was documented.
In the overall population, the number of migraine attacks decreased to 0.8 (0.3–2.0) at endpoint. The reduction in migraine attacks was statistically significant compared to baseline at all visits and for the ITT population.

**Number of days with migraine**

The median (IQR) number of migraine days decreased from 6.0 (5.0–8.0) days at baseline to 1.2 (0.5–2.5) days at month 6 (Fig. 2b). At the end of the follow-up period (month 12), the median (IQR) for migraine days was 0.7 (0.3–1.8) and 0.9 days (0.4–2.7) in the ITT population. The reduction in the number of migraine days was statistically significant compared to baseline ($p < 0.001$) at all visits and for the ITT population. Six patients were identified who had 15 or more migraine days during their baseline. Due to the small number, no further analyses were done.

**Responder rates**

Migraine attacks were reduced by at least 50% in 28.1% of patients (i.e. 85 out of 302 patients) after 2 weeks of treatment with topiramate and by at least 75.9% at end of core phase (6 months). Outcomes remained stable during the follow-up phase (month 9: 80.8%, month 12: 79.2%). Results were similar in the ITT population. Here, 76.8% achieved at least 50% reduction in migraine attacks (Fig. 3).

A clinically relevant proportion of patients achieved complete freedom of migraine headaches (100% reduction). The percentage increased from 13.9% after 2 weeks to

---

**Table 3** Frequency and type of previous migraine prevention in EFF population ($N = 302$)

| Patients with preventive treatment | 139 (46.0) |
|-----------------------------------|------------|
| Number of therapeutic trials/drugs used | 1–2 | 3–4 | 5–10 | >10 |
| Beta blockers | 115 (82.7) | 7 (5.0) | 1 (0.7) | 1 (0.7) |
| Ca$^{2+}$-channel blockers | 37 (26.6) | | 1 (0.7) |
| Anticonvulsants | 23 (16.5) | | |
| Antidepressives | 43 (30.9) | 2 (1.4) | 1 (0.7) |
| Other | 14 (10.1) | 3 (2.2) | 1 (0.7) |

---

**Fig. 2** (a) Number of migraine attacks. (b) Number of days with migraine. Asterisk Number of attacks and days were normalized to a period of 28 days

**Fig. 3** Responder rates for the number of migraine attacks and the mean number of days with migraine. Percentages relate to the number of patients with documented visits. Responder rates for days with migraine headache are not described in the text
18.2%, 21.6%, and 22.1% after 4, 8, and 12 weeks. At the two follow-up visits, the proportion of patients with 100% reduction in migraine attacks reached approximately 21% (month 9: 20.7%, month 12: 20.8%). The calculated LOCF was 21.2%.

**Pain intensity scores**

Figure 4 illustrates the decrease in the pain intensity score results in the course of the study period. The median (IQR) migraine intensity score decreased in patients with remaining migraine over time. At baseline, a score of 17.0 (12.0–24.0) points was calculated in 294 patients, declining to 12.0 (7.5–19.4) points at week 2 (N = 257), 4.6 (2.8–9.3) points at week 8 (N = 224), and 3.2 (1.5–6.2) points at month 6 (N = 228). During follow-up, further decrease was noted with the lowest value of 2.0 (1.0–5.0) points achieved at month 12 (N = 142). The median (IQR) LOCF was 2.6 (1.3–7.0) points (N = 298). Changes from baseline were statistically significant (p < 0.001) at all visits as well as for the ITT population.

**Migraine with aura**

At baseline, 81 out of 302 patients (26.8%) reported migraine with aura, 215 patients (71.2%) had no aura, and data were missing for 6 patients (2.0%). During the course of study, the proportion of patients with reported aura decreased. At month 6, only 17 patients (6.5%) and at month 12, only 12 patients (6.6%) reported migraine with aura.

**Migraine and menstruation**

A subanalyses explored efficacy outcomes in women with and without menstruation associated migraines. Results are based on women’s reportings. A distinction between menstruation related migraines (MRM) and pure menstrual migraines (PMM) was not applied [22].

In women without MRM, the median (IQR) monthly number of migraine attacks was 4.0 (3.0–6.0) at baseline (N = 167). The median values decreased to 3.7 (2.0–6.0) at week 2 (N = 163) and decreased further to 0.9 (0.4–2.0) at month 6 (N = 147), and 0.6 (0.3–1.2) at month 12 (N = 95). The median LOCF was 0.7 (0.3–2.0; N = 167). Changes from baseline were statistically significant (p ≤ 0.002) at all visits and for the ITT population.

In women with MRM, baseline migraine attack frequency as well as treatment response were similar. The median (IQR) monthly number of migraine attacks was 4.0 (3.0–6.0) at baseline (N = 96) and decreased to 2.8 (1.8–6.0) at week 2 (N = 96), to 0.9 (0.3–1.6) at month 6 (N = 80), and 0.6 (0.0–1.5) at month 12 (N = 59). The median LOCF was 0.8 (0.3–2.0; N = 98). Changes from baseline were statistically significant (p ≤ 0.024) at all visits and for the ITT population (Table 4).

**Impairment of activities in daily life**

The impairment of daily life is illustrated in Fig. 5. The median (IQR) impairment score decreased from 16.0 (12.0–23.0) points at baseline (N = 294) to 2.1 (0.7–4.7) points at month 6 (N = 258), and further to 1.3 (0.3–3.3) points at month 12 (N = 172). The median LOCF was 1.7 (0.3–5.3; N = 301). The changes from baseline were statistically significant (p < 0.001) at all visits and for the ITT population.

**Absenteeism**

The mean number of days decreased from 2.1 ± 2.4 days at baseline (N = 298) to 1.2 ± 2.6 days at week 2 (N = 296), 0.3 ± 0.6 days at month 6 (N = 257), and 0.1 ± 0.3 days at month 12 (N = 172). Mean LOCF was 0.3 ± 1.0 days (N = 302). The changes from baseline were statistically significant (p < 0.001) at all visits and for the LOCF.
Quality of life (questionnaire HIT-6™)

At baseline, patients started with clinically relevant impairment as measured by HIT-6™. The sum score changed from 65.2 ± 4.6 (median: 65.0, IQR: 63.0–68.0; N = 298) to 51.7 ± 8.8 at month 6 (median: 52.0, IQR: 46.0–58.0; N = 254, unknown N = 7), and to 47.5 ± 8.2 at month 12 (median: 48.0, IQR: 40.0–54.0; N = 177, unknown N = 6). The mean LOCF was 48.8 ± 8.8 (median: 48.0, IQR: 42.0–56.0; N = 265). The changes from baseline were statistically significant (p < 0.001) at all time points and for the ITT population LOCF (Fig. 6).

Therapy satisfaction (tolerability and prophylactic efficacy)

The physicians assessed tolerability of topiramate as at least “good” in over 90% of patients (i.e. 97.3% at month 12). The proportion of patients for whom tolerability was rated “very good” increased during the course of the study:

Table 4 Migraine associated with menstruation

|                   | Baseline N = 302 | Week 12 N = 272 | Month 6 N = 261 | Month 9 N = 203 | Month 12 N = 183 | LOCF N = 235 |
|-------------------|------------------|-----------------|-----------------|-----------------|-----------------|--------------|
| **Patients N (%)**|                  |                 |                 |                 |                 |              |
| Women with documented visits a  | 266 (88.1)       | 240 (88.2)      | 230 (88.1)      | 180 (88.7)      | 164 (89.6)      | 235 (100)    |
| Women with migraine attacks b  | 259 (97.4)       | 177 (73.8)      | 196 (85.2)      | 134 (74.4)      | 119 (72.6)      | 187 (79.6)   |
| Association with menstruation c  |                  |                 |                 |                 |                 |              |
| No                  | 165 (63.7)       | 137 (77.4)      | 145 (74.0)      | 93 (69.4)       | 88 (73.9)       |              |
| Yes                 | 94 (36.3)        | 35 (19.8)       | 45 (23.0)       | 40 (29.9)       | 31 (26.1)       | 42 (22.5)    |

a Percentages relate to the number of patients with documented visits
b Percentages relate to the number of women with documented visits
c Percentages relate to the number of women with migraine attacks
d Total count of women for whom migraine attacks associated with menstruation were observed for the first time after treatment with topiramate

Fig. 5 Impairment of daily life. Asterisk Impairment score = (days with severe impairment × 3) + (days with moderate impairment × 2) + (days with slight impairment × 1)

Quality of life according to the HIT-6™ questionnaire

48.9% (N = 133) at week 12, 51.0% (N = 133) at month 6, and 63.4% (N = 116) at month 12. Tolerability was considered “not satisfactory” for one patient at week 12 (0.4%) and for one patient at month 12 (0.5%). The LOCF (N = 271) yielded very good tolerability for 57.2%, good tolerability for 36.5%, satisfactory tolerability for 5.5%, and not satisfactory tolerability for 0.7% of patients.

Similarly, the physicians assessed the efficacy outcomes of topiramate as at least “good” in over 85% of patients (86.4% at week 12, 94% at month 12). Patients’ assessment was very similar to the physicians’ assessment after 12 weeks of treatment and at the end of the observational period (month 6). The LOCF yielded very good efficacy in 49.8%, good efficacy in 39.1%, satisfactory efficacy in 6.3%, and not satisfactory efficacy in 4.8% out of 271 patients.

Acute medication

During the 28 days prior to treatment with topiramate, patients took triptans at 4.9 ± 3.4 days (median: 5 days,
Other acute migraine medications was 3.1 ± N = 289). Other acute migraine medications were taken on average at 9.2 ± 11.5 days (median: 5 days, IQR: 3–12 days, N = 41). During the study, the number of acute treatment days declined. At week 2, the mean number of days with triptan treatment had dropped to 3.8 ± 4.8 days (median: 2 days, N = 286) and was further decreased to 1.6 ± 3.8 days at month 6 (median: 1 day, N = 254) and to 1.0 ± 2.6 days at month 12 (median: 0 days, N = 163). On average, other analgetics were used for 1.3 ± 3.0 days at month 6 (median: 0 days; N = 248) and 0.9 ± 1.1 days at month 12 (median: 0 days, N = 163), while the mean sum of days of all other acute migraine medications was 3.1 ± 5.6 days at month 6 (median: 1 day, N = 49) and 1.4 ± 0.8 days at month 12 (median: 1 day, N = 27).

Tolerability

In the course of the study, 101 AEs were reported in 46 patients (13.7% of 336 patients) (Table 5). A relationship to treatment with topiramate (possible, or probable, or highly probable) was reported for 64 AEs in 35 patients (10.4%) by the treating physician, including two serious (highly probable) was reported for 64 AEs in 35 patients (13.7% of 336 patients) (Table 5). A relationship to topiramate for 1.3 ± 2.1 days at month 6 (median: 0 days; N = 254) and to 1.0 ± 2.6 days at month 12 (median: 0 days, N = 163), while the mean sum of days of all other acute migraine medications was 3.1 ± 5.6 days at month 6 (median: 1 day, N = 49) and 1.4 ± 0.8 days at month 12 (median: 1 day, N = 27).

Table 5 Summary of adverse events

| All patients N (%) |  |
|--------------------|---|
| Number of patients treated | 336 |
| All adverse events | 101 |
| Number of adverse events | 101 |
| Patients with adverse events | 46 (13.7) |
| Patients with serious adverse events | 2 (0.6) |
| Number of deaths | 0 (0.0) |
| Related adverse events | 64 |
| Number of adverse events | 64 |
| Patients with adverse events | 35 (10.4) |
| Patients with serious adverse events | 1 (0.3) |
| Number of deaths | 0 (0.0) |

Percentages relate to patients dosed
Related = possible + probable + likely relationship with topiramate

Table 6 Number of patients with reported adverse events (AEs) during the whole study (safety-sample)

|                  | Total | Related
|------------------|-------|----------|
|                  | N     | %       | N     | %       |
| At least one AEb | 46    | 13.7    | 35    | 10.4    |
| At least one AE from the following classb | | | |
| Paraesthesia | 10 | 3.0 | 9 | 2.7 |
| Dizziness | 4 | 1.2 | 4 | 1.2 |
| Diarrhea | 5 | 1.5 | 4 | 1.2 |
| Nausea | 14 | 4.2 | 8 | 2.4 |
| Fatigue | 4 | 1.2 | 4 | 1.2 |
| Vomiting | 4 | 1.2 | 1 | 0.3 |

Listed are adverse events occurring in >3 patients in the total sample

a AEs with possible, probable, or very probable causal relationship (CR) with topiramate as assessed by the investigator
b Multiple events possible

assessment, the SAE was considered as being “possibly” related to topiramate therapy. No further cardio-vascular risk factors were identified. The patient had not fully recovered at the time of the conclusion of the study report. She has been discharged to a rehabilitation center.

The second patient was a 52-year-old woman with a history of episodic migraine for the last 20 years who presented with weight loss. Subsequently, the patient was diagnosed with pituitary insufficiency secondary to a cranioopharyngeoma and underwent microsurgical removal. The relationship to topiramate therapy was rated as unlikely. No deaths occurred during the study.

As shown in Table 6, the most frequently reported symptoms were nausea (total: N = 14, 4.2%; related: N = 8, 2.4%), paresthesia (total: N = 10, 3.0%; related: N = 9, 2.7%), and vomiting (N = 4, 1.2%). Adverse events reported only in few patients were: fatigue (total and related: N = 4, 1.2%), diarrhea (total: N = 5, 1.5%, related: N = 4, 1.2%), and dizziness (total and related: N = 4, 1.2%). All other symptoms were reported by <3 patients.

The mean weight of the patients was stable in the course of the study. At baseline, the mean weight of the 302 patients was 68.6 ± 11.3 kg (median: 67 kg, IQR range 60–75 kg). At the end of the follow-up period (month 12) the mean weight of the remaining 183 patients was 68.1 ± 10.5 kg (median: 68 kg, IQR: 60–74 kg).

Discussion

In this open label study, tolerability and efficacy outcomes of topiramate for preventive migraine therapy were explored in 336 patients seen in private practices or...
ambulatory care centers. These practitioners are important for successful management of the majority of migraine patients who do not require pain management in a tertiary care center. Both, tolerability and efficacy results in this setting compare well to published data of controlled and open label trials conducted in specialized academic institutions [12, 13, 23, 24].

In 35 patients (10.4%), at least one treatment-related AE were reported. The most frequent AE was paresthesia in 10 patients (3.0%). In previous controlled trials, paresthesia was also the most common topiramate-associated AE (35%, 51%, and 49% of patients receiving topiramate 50 mg/day, 100 mg/day, or 200 mg/day, respectively [6% on placebo]), and thus, higher compared to this study [13, 24, 25]. Incidence of paresthesias in patients treated with topiramate, however, vary considerably across studies with generally lower frequencies in open-label compared to controlled studies. In a recent open label study of topiramate in epilepsy patients, paresthesia was observed in 8.0% of patients [26]. The other important AE of this study was nausea (4.2%). All other symptoms of AEs (Table 6), such as fatigue (1.2%), dizziness (1.2%), impaired attention (0.9%), anorexia (0.9%), and weight loss (0.6%) occurred less frequently. In a pooled analysis of randomized controlled trials, similar frequencies were observed for nausea (8.9%), fatigue (11.8%), dizziness (9.7%), and weight loss (1.3%). Topiramate-associated AEs are mild or moderate in severity and occur at consistently higher rates during the titration period compared to the maintenance period of the double-blind phase. Paresthesia, nausea fatigue, and dizziness were also commonly reported AEs in a recent large open label study of topiramate in migraine prevention [21].

The discontinuation rate during the 6 months core phase due to AEs was low. Overall, 77.7% of all patients completed the 6 months core phase. Among 75 patients who discontinued prematurely (22.3% of SAF), 7 patients (2.1%) had AEs. The most frequent symptoms in these patients were fatigue and nausea, each reported for two patients, respectively. In almost 75% of patients the reason for discontinuation is unknown and no further information was obtainable. Even if all of these patients discontinued due to adverse events, the effectiveness and retention on treatment compares well to other open label studies and provides additional support for the ease of use and tolerability of topiramate in daily routine for migraine prevention.

As much as 183 patients (54.5% of SAF) completed the full 12-months observation and follow-up period) including Visit 8. Treatment discontinuation due to AE in previous controlled studies with topiramate was higher, likely due to higher doses in those studies as well as fixed titration schedule [25]. AE-related drop-outs were dose-dependent in all randomized controlled trials [25, 27].

The lower incidence of commonly reported AE’s with topiramate and AE-related discontinuation rate of this study is likely due to the lower average daily dose of 57.8 mg topiramate in this study as well as the individualized treatment approach. The 6 months follow up period was optional and reasons for treatment continuation were not formally assessed. The study was conducted at a time when several treatment guidelines recommended discontinuation of preventive therapy after 3–6 months [28]. This has to be contrasted to clinical practice. In some patients, longer treatment continuation might be beneficial. A recently published double-blind placebo controlled study supports this view by showing continued benefit of therapy for 6 months to up to one year [12]. Recently published data even suggest that approximately 50% of patients might actually benefit from migraine prevention for more than one year [29]. The number of patients who might qualify for a diagnosis of chronic migraine was low, therefore, a subanalyses of treatment response in this patient group was not performed. Recent data suggest that topiramate is effective in chronic migraine treatment [41].

The study population was predominantly female (87%, SAF). Based on epidemiological data, a higher proportion of men would be expected [2, 30]. An explanation might be the lower rate of diagnosis in men compared to women which is suggested by the American migraine study. Though close to 50% of affected individuals are diagnosed, the proportion of men with a diagnosis reaches only 30% [31]. In addition, as shown in the American migraine prevalence and prevention study, current or ever use of preventive medication was more likely in women than in men (odds ratio [OR] = 1.37, 95% confidence interval [CI] 1.27–1.48), increased with age and individuals with high MIDAS grade (Grade IV vs. I, OR 2.35, 95% CI 2.09–2.64) [32]. In addition, a higher rate of vocational activity among men may result in limited interest to participate in an open label study resulting in an artificially low number of participants. Post-hoc analyses based on the pivotal trials do not suggest a differential response in women or men as another possible explanation [24].

After 6 months of treatment, patients receiving topiramate had less than one migraine attack per month. The median number of migraine attacks declined from 4.0 to 0.9. The preventive treatment effect was maintained throughout the follow-up phase. The number of migraine days per month was also significantly reduced. Treatment with topiramate was also associated with significant improvements for several other migraine treatment effect measures, such as pain intensity and consumption of analgesics. At the end of the 6 months core phase, the frequency of migraine attacks could be reduced by at least 50% compared to baseline for 76% of patients. The proportion of patients with more than 50% migraine reduction

\[ \text{\textcopyright} \text{Springer} \]
reached 80% during the follow-up period. As much as 21% of all patients were completely free of migraine attacks at the end of the follow-up phase.

The efficacy data of this study are comparable with those of randomized controlled trials. Brandes reported a 40% reduction in migraine frequency for daily doses of 100 mg and a 42% reduction for daily doses of 200 mg at 6 months endpoint [25]. Similar reduction rates were also observed in other controlled trials [13]. Results from these placebo-controlled trials, however, suggest that even total daily doses at 50 mg might have a significant effect compared to placebo or show at least incremental benefit. In this study, topiramate was dosed between 25 and 200 mg/day with a mean daily dose of 58.7 ± 27.7 mg, indicating that reduction of migraine days and pain intensity can be achieved with lower levels of topiramate.

Menstrual migraine was observed in 36% of female migraineurs which is lower than the 50% expected based on epidemiological data [33]. In this subgroup of women in our study, a clinically relevant reduction of migraine attacks after 6 months was observed. Compared to non-menstrual migraine, menstrual migraine attacks are often more severe, longer in duration, and have a poorer response to analgesics. Epidemiological, pathophysiologic, and clinical evidences link estrogen to migraine headaches [34, 35]. For the preventive treatment of menstrual migraine, there are grade B recommendations for the perimenstrual use of transcutaneous estrogen 1.5 mg. Also, frovatriptan 2.5 mg twice daily and naratriptan 1 mg twice daily have shown efficacy in prevention of menstrual migraine [22]. None of these agents was used in our patients. Even considering the limitations of this study by not having defined menstruation-related migraines according to the international headache society criteria [22], these data may suggest that menstrual migraine attacks respond to preventive treatment with topiramate. A post-hoc analyses based on a recently published trial is supportive of this view [12].

We also observed significant improvement on measurements of daily living activities and health related quality of life. In the course of the 12-month study period, the median impairment score decreased from 16.0 to 1.3 points and the HIT-6™ score sum decreased from 65.0 to 48.0 points. The improvement of functional outcome with topiramate migraine prophylaxis is exemplified by the reduction of days absent from work (from a median of 2.0 days per month at baseline to 0.0 days after treatment). Similar observations have been reported from other studies using health-related quality of life endpoints, such as Migraine Specific Questionnaire (MSQ) and the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) [36]. In a 3-month prospective study of 103 migraine patients, for example, all SF-36 items improved after patients were started on pharmacologic migraine prophylaxis [37].

Improved health-related quality of life outcome and vocational activities are prime objectives of preventive migraine therapy. Preventive therapy with topiramate was shown to be associated with significant decreases in resource use based on pharmacy data claim analyses [9] as well as an increased work place productivity based on results of randomized controlled trials [38].

The observed treatment effects of an open label study need to be interpreted with caution. Several controlled studies have demonstrated a powerful placebo-effect in migraine prevention [39]. In one meta-analysis of all placebo-controlled studies of propranolol for prevention of migraine, the response rate for propranolol was 55.1% and for placebo 14.3% [40]. A very recent meta-analysis reported placebo responder rates of 21%. In the current study, the extent of reduction in migraine attacks, migraine days, maximum pain intensity, and consumption of analgesics, however, is comparable to responder rates of active substances in controlled studies. Therefore, the improved migraine control observed in this study cannot be attributed to a placebo effect alone.

The results of the current study further support that topiramate is generally well tolerated and effective in migraine prevention when administered by non-specialized physicians. Topiramate showed significant reduction in the frequency of migraine attacks, migraine days, pain intensity, and improvement on health-related quality of life outcomes. These results may spur the effort to improve the current underutilization of pharmacologic migraine prevention outside tertiary or specialized care.

Acknowledgments We thank the study coordinators from Janssen-Cilag, Germany for their contribution and Kerstin Schuppien and Tanja Hendrichs, PhD, for editorial assistance with the manuscript.

Conflict of interest Dr. Bornhoevd and Dr. Schauble are full time employees of Janssen-Cilag EMEA, Neuss, Germany. The study was conducted by Medidata, Konstanz, Germany and Dr. Fritz sche served as a consultant for the statistical analysis. The study has been sponsored by Janssen-Cilag Germany.

Appendix

We gratefully acknowledge the participation of following TOPMAT-MIG-0001 investigators: Thomas Wegner, Königstein; Hans Werner Fischer, Friedrichsthal; Bernhard Wolfram, Mannheim; Karin Schindlbeck, Parsberg; Susanne Peters, Dortmund; Ursula Schax, Essen; Eva M. Dietz, Bamberg; Juergen Haas, Nürnberg; Markus Föh, Fulda; D. Katholnigg, Mönchengladbach; Gerd Rauch, Bayreuth; Martin Kühn, München; Veit-Ulrich Becker, Hamburg; Michael Springer, Pirmasens; Guido M. Auner, Lüdenscheid; Kristin Hontzek, Dommitzsch; Heinz-Wilhelm
8. Silberstein SD, Goadsby PJ, Lipton RB (2000) Management of migraine: an algorithmic approach. Neurology 55:S46–S52
9. Silberstein SD, FelIU AL, Rupnow MF, Blount AC, Boccuzzi SJ (2007) Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache 47:500–510
10. Diener HC, Brune K, Gerber WD, Pfaffenrath V, Straube A (2000) Therapy of the acute migraine attack and migraine prophylaxis. Recommendation of the “Deutsche Migrane- und Kopfschmerz-Gesellschaft. Schmerz 14:269–283
11. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J (2009) Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 31:542–559
12. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Del Rio MS, Schoenen J, Schwalen S, van Oeue OJ (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054–1062
13. Diener HC, Tfelt-Hansen P, Dahlöf C, Lainez MJ, Sandrini G, Wang SJ, Neto W, Vijapurkar U, Doyle A, Jacobs D (2004) Topiramate in migraine prophylaxis—results from a placebo-controlled trial with propranolol as an active control. J Neurol 251:943–950
14. Diener HC, Matias-Guiu J, Hartung E, Paffennath V, Ludin HP, Nappi G, De Beukelaar F (2002) Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 22:209–221
15. Silberstein SD (2004) Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol Sci 25(Suppl 3):S244–S245
16. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL (1995) Migraine prophylaxis with divalproex. Arch Neurol 52:281–286
17. Pascual J, El BY, Gomez-Sanchez JC (2007) How many migraine patients need prolonged (> 1 year) preventive treatment? Experience with topiramate. J Headache Pain 8:90–93
18. Silberstein SD, Neto W, Schmitt J, Jacobs D (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61:490–495
19. Treatment Guideline Subcommittee of the Taiwan Headache Society (2008) Treatment guidelines for preventive treatment of migraine. Acta Neurol Taiwan 17:132–148
20. Lanteri-Minet M, Delbru ¨ ck A, Schulze l, Kademann B, Bornhoevd K (2008) The role of general practitioners in migraine management. Cephalalgia 28(Suppl 2):1–8
21. Brandes JL (2002) Global trends in migraine care: results from the MAZE survey. CNS Drugs 16(Suppl 1):13–18
22. Schnei der HC, Tfelt-Hansen P, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL (1995) Migraine prophylaxis in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 28:1002–1011
23. Rapoport A, Maukop A, Diener HC, Schwalen S, Pfeil J (2006) Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache 46:1151–1160
24. Bussone G, Diener HC, Pfeil J, Schwalen S (2005) Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 59:961–968
25. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwale S, Jacobs D (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965–973
26. Kurth C, Schauble B, Schreiner A, Retting K, Steinhoff BJ (2009) Exploring efficacy and tolerability outcomes in patients with difficult-to-treat epilepsy receiving adjunctive topiramate at different titration rates—an exploratory study. Acta Neurol Scand 120:80–87
27. Silberstein SD, Neto W, Schmitt J, Jacobs D (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61:490–495
28. Martin VT, Lipton RB (2008) Epidemiology and biology of menstrual migraine. Headache 48(Suppl 3):S124–S130
29. MacGregor EA (1997) Menstruation, sex hormones, and migraine. Neurol Clin 15:125–141
30. MacGregor EA (1996) “Menstrual” migraine: towards a definition. Cephalalgia 16:11–21
31. Martin VT, Lipton RB (2008) Topiramate for the treatment of the acute migraine attack and migraine prophylaxis—results of a large controlled trial. Arch Neurol 61:490–495
32. Martin VT, Lipton RB (2008) Topiramate for the treatment of the acute migraine attack and migraine prophylaxis—results of a large controlled trial. Arch Neurol 61:490–495
33. Mathew NT, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwale S, Jacobs D (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965–973
34. Kurth C, Schauble B, Schreiner A, Retting K, Steinhoff BJ (2009) Exploring efficacy and tolerability outcomes in patients with difficult-to-treat epilepsy receiving adjunctive topiramate at different titration rates—an exploratory study. Acta Neurol Scand 120:80–87
35. Diener HC, Schorn CF, Bingel U, Dodick DW (2008) The importance of placebo in headache research. Cephalalgia 28:1003–1011
36. Holroyd KA, Penzien DB, Cordingley GE (1991) Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31:333–340
37. Diener HC, Schorn CF, Bingel U, Dodick DW (2008) The importance of placebo in headache research. Cephalalgia 28:1003–1011
38. Holroyd KA, Penzien DB, Cordingley GE (1991) Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31:333–340
39. Diener HC, Schorn CF, Bingel U, Dodick DW (2008) The importance of placebo in headache research. Cephalalgia 28:1003–1011
40. Holroyd KA, Penzien DB, Cordingley GE (1991) Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31:333–340
41. Diener HC, Schorn CF, Bingel U, Dodick DW (2008) The importance of placebo in headache research. Cephalalgia 28:1003–1011